temoporfin
Temoporfin (INN) is a photosensitizer used in photodynamic therapy for the treatment of squamous cell carcinoma of the head and neck. It is marketed in the European Union under the brand name Foscan. The U.S. Food and Drug Administration (FDA) declined to approve Foscan in 2000. The EU approved its use in June 2001. — Wikipedia
Clinical trial activity
8 trials · 14 clinical orgs · 0 marketing orgs
Earliest trial started Oct 1, 1998 (NCT00003856)
Timeline
Indications
Mechanism of action
- Unspecified targetOTHER
Photosensitizer
Temoporfin is taken up by tumor cells. Its activity is initiated by photoactivation with non-thermal light at a wavelength of 652 nm. The cytotoxic effect is mediated through the generation of highly reactive oxygen species, such as singlet oxygen, resulting from intracellular interaction of temopor¿n with light and oxygen. These reactive oxygen species cause the loss of cell viability.
Chemistry & pharmacology
SMILES
Oc1cccc(-c2c3nc(c(-c4cccc(O)c4)c4ccc([nH]4)c(-c4cccc(O)c4)c4ccc([nH]4)c(-c4cccc(O)c4)c4nc2CC4)C=C3)c1- Mol. weight
- 680.76 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTemoporfin ↗
- ChEMBLCHEMBL500576 ↗
- ChEMBLCHEMBL383675 ↗
Also known as
- 5,10,15,20-tetra(m-hydroxyphenyl)chlorin
- ef9
- ef9
- foscan
- foscan
- foscan
- foscan
- fosgel
- foslip
- foslipos
- meso-tetrahydroxyphenylchlorin
- meso-tetra-(hydroxyphenyl)chlorin
- meso-tetrahydroxyphenyl chlorin
- mthpc
- mthpc
- mthpc
- m-thpc
- temoporfin
- temoporfin
- temoporfin
- temoporfin
- temoporfin
- temoporfin
- temoporfin
- temoporfin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01854684 | Phase 1 | Feb 21, 2014 | National Cancer Institute (NCI), State University of New York, Buffalo |
| NCT03003065 | Phase 2 | Jan 1, 2014 | Chinese University of Hong Kong |
| NCT01718223 | N/A | Dec 1, 2013 | Biolitec Pharma Ltd., National Institutes of Health (NIH), State University of New York, Buffalo |
| NCT01637376 | Phase 1 | Jul 1, 2012 | Hoosier Cancer Research Network |
| NCT01415986 | Phase 2 | Nov 1, 2010 | Biolitec Pharma Ltd., Erasmus University Rotterdam, Hoosier Cancer Research Network, Netherlands Cancer Institute |
| NCT01086488 | Phase 2 | Jan 1, 2009 | Government of Malaysia, University Putra Malaysia |
| NCT01016002 | Phase 2 | Jan 1, 2006 | Biolitec Pharma Ltd., Paracelsus Medical University, University of Hamburg, University of Salzburg |
| NCT00003856 | Phase 2 | Oct 1, 1998 | IQVIA |
Organizations
Research & Development (14)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biolitec Pharma Ltd. | For profit | 3 | 0 | 2 | 2006 |
| Hoosier Cancer Research Network | Academic/Hospital | 2 | 2 | 2 | 2010 |
| State University of New York, Buffalo | Academic/Hospital | 2 | 2 | 2 | 2013 |
| Chinese University of Hong Kong | Academic/Hospital | 1 | 1 | 1 | 2014 |
| Erasmus University Rotterdam | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Government of Malaysia | Government | 1 | 1 | 1 | 2009 |
| IQVIA | For profit | 1 | 1 | 1 | 1998 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2014 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2013 |
| Netherlands Cancer Institute | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Paracelsus Medical University | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of Hamburg | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of Salzburg | Academic/Hospital | 1 | 1 | 1 | 2006 |
| University Putra Malaysia | Academic/Hospital | 1 | 0 | 1 | 2009 |